Researchers have demonstrated that optogenetic gene therapy, a technique leveraging Nobel prize-winning science, is safe and capable of partially restoring vision in people with severe blindness. The approach was initially shown to work in a single patient in 2021 and has now been evaluated in a larger clinical trial encompassing that original patient plus nine additional participants.
The therapy targets advanced retinitis pigmentosa, a genetic disorder in which light-sensitive cells in the retina progressively deteriorate. Rather than attempting to restore the damaged photoreceptor cells, the treatment works on ganglion cells in the retina that remain relatively intact. The procedure involves a single injection into the eye using a harmless synthetic virus to deliver genetic instructions for producing a light-sensitive protein, effectively making these cells responsive to light.
Following treatment, patients receive specialized goggles that capture images and convert them into pulses of light. These light pulses activate the treated ganglion cells, enabling patients to perceive monochrome visual information. According to findings published in the New England Journal of Medicine, six of the ten trial participants experienced clinically meaningful improvements in light sensitivity. Several patients demonstrated functional gains in specific tasks, including detecting and locating objects and navigating spaces, with better outcomes associated with increased training time with the goggles.
The approach proved largely safe, with only one severe eye-related side effect occurring across the trial, which resolved quickly, and no systemic side effects reported. However, researchers note current limitations, as patients can detect objects but cannot yet recognize faces, a constraint attributed to the ring-like arrangement of treated cells around the fovea. Lead researcher Prof Botond Roska indicated that the team aims to work toward high-resolution vision restoration within five to ten years.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI